Tonix Pharmaceuticals Holding Corp. Forecasted to Earn Q1 2024 Earnings of ($0.31) Per Share (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Zacks Small Cap issued their Q1 2024 earnings per share (EPS) estimates for Tonix Pharmaceuticals in a note issued to investors on Monday, April 29th. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($0.31) for the quarter. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($3.71) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals’ FY2026 earnings at ($0.62) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.86) EPS for the quarter. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million.

A number of other analysts have also issued reports on the stock. Dawson James assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a “buy” rating and a $3.00 target price for the company. StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Saturday. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Trading Up 6.5 %

Shares of TNXP opened at $0.18 on Tuesday. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $3.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. The company’s fifty day simple moving average is $0.27 and its 200-day simple moving average is $0.37.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Sabby Management LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals accounts for 0.5% of Sabby Management LLC’s portfolio, making the stock its 6th largest holding. Sabby Management LLC owned approximately 7.02% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.